Development of therapeutics for treatment of Ebola virus infection

Microbes and Infection

Volumn 17, Issue 2, 2015, Pages 109-117

  Li, Haoyang ^a   Ying, Tianlei ^a   Yu, Fei ^a   Lu, Lu ^a   Jiang, Shibo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

Antibody; Ebola virus; Ebola virus disease; Small molecule compounds; Therapeutics; Treatment

Indexed keywords

ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; OLIGONUCLEOTIDE; VIRUS FUSION INHIBITOR; VIRUS RNA; EBOLA VACCINE;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; ARTICLE; DRUG SCREENING; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HUMAN; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVERSE GENETICS; RNA SYNTHESIS; RNA TRANSLATION; VESICULOVIRUS; VIREMIA; VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; EBOLAVIRUS; GENETICS; HEMORRHAGIC FEVER, EBOLA; VIROLOGY;

EBOLA VIRUS;

ANIMALS; ANTIVIRAL AGENTS; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; RNA, VIRAL; VIRUS INTERNALIZATION;

EID: 84921613207     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.11.012     Document Type: Article

References (107)

1. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978, 56:271-293.
2. Knipe D.M., Howley P.M. Fields virology 2013, Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia, PA.
3. Butler D., Morello L. Ebola by the numbers: the size, spread and cost of an outbreak. Nature 2014, 514:284-285.
4. Boozary A.S., Farmer P.E., Jha A.K. The ebola outbreak, fragile health systems, and quality as a cure. JAMA 2014.
5. Incident Management System Ebola Epidemiology Team CDC Ministries of health of Guinea SLLN, Senegal, viral special pathogens branch NCfE, zoonotic infectious diseases CDC. Ebola virus disease outbreak - west africa, september 2014. MMWR Morb Mortal Wkly Rep 2014, 63:865-866.
6. To K., Chan J., Tsang A., Cheng V., Yuen K.Y. Ebola virus disease: a highly fatal and panic-generating infectious disease reemerging in West Africa. Microbes Infection/Institut Pasteur 2015, [Epub ahead of print].
7. Gulland A. Fifteen countries are at risk of Ebola outbreak, says WHO. BMJ 2014, 349:g6305.
8. Poletto C., Gomes M., Pastore Y.P.A., Rossi L., Bioglio L., Chao D., et al. Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic. Euro Surveill 2014, 19.
9. Situation reports: ebola response roadmap. World Health Organization. (accessed 06.11.14). http://www.who.int/csr/disease/ebola/situation-reports/en/.
10. Feldmann H., Geisbert T.W. Ebola haemorrhagic fever. Lancet 2011, 377:849-862.
11. Bray M. Defense against filoviruses used as biological weapons. Antivir Res 2003, 57:53-60.
12. Kortepeter M.G., Bausch D.G., Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011, 204(Suppl. 3):S810-S816.
13. Hoenen T., Groseth A., Feldmann H. Current ebola vaccines. Expert Opin Biol Ther 2012, 12:859-872.
14. Marzi A., Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 2014, 13:521-531.
15. Mullard A. Experimental Ebola drugs enter the limelight. Lancet 2014, 384:649.
16. Clark D.V., Jahrling P.B., Lawler J.V. Clinical management of filovirus-infected patients. Viruses 2012, 4:1668-1686.
17. Ye L., Yang C. Development of vaccines for prevention of Ebola virus infection. Microbes Infection/Institut Pasteur 2015, [Epub ahead of print].
18. Li Y.H., Chen S.P. Evolutionary history of Ebola virus. Epidemiol Infect 2014, 142:1138-1145.
19. Baize S., Pannetier D., Oestereich L., Rieger T., Koivogui L., Magassouba N., et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014, 371:1418-1425.
20. Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol 2014, 95:1619-1624.
21. Bharat T.A., Noda T., Riches J.D., Kraehling V., Kolesnikova L., Becker S., et al. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc Natl Acad Sci U S A 2012, 109:4275-4280.
22. Geisbert T.W., Jahrling P.B. Differentiation of filoviruses by electron microscopy. Virus Res 1995, 39:129-150.
23. Huang Y., Xu L., Sun Y., Nabel G.J. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell 2002, 10:307-316.
24. John S.P., Wang T., Steffen S., Longhi S., Schmaljohn C.S., Jonsson C.B. Ebola virus VP30 is an RNA binding protein. J Virol 2007, 81:8967-8976.
25. Modrof J., Becker S., Muhlberger E. Ebola virus transcription activator VP30 is a zinc-binding protein. J Virol 2003, 77:3334-3338.
26. Noda T., Kolesnikova L., Becker S., Kawaoka Y. The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation. J Infect Dis 2011, 204(Suppl. 3):S878-S883.
27. Trunschke M., Conrad D., Enterlein S., Olejnik J., Brauburger K., Muhlberger E. The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology 2013, 441:135-145.
28. Hartlieb B., Weissenhorn W. Filovirus assembly and budding. Virology 2006, 344:64-70.
29. Hunt C.L., Lennemann N.J., Maury W. Filovirus entry: a novelty in the viral fusion world. Viruses 2012, 4:258-275.
30. Lee J.E., Fusco M.L., Hessell A.J., Oswald W.B., Burton D.R., Saphire E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008, 454:177-182.
31. Moller-Tank S., Albritton L.M., Rennert P.D., Maury W. Characterizing functional domains for TIM-mediated enveloped virus entry. J Virol 2014, 88:6702-6713.
32. Hood C.L., Abraham J., Boyington J.C., Leung K., Kwong P.D., Nabel G.J. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol 2010, 84:2972-2982.
33. Chandran K., Sullivan N.J., Felbor U., Whelan S.P., Cunningham J.M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005, 308:1643-1645.
34. Harrison J.S., Higgins C.D., Chandran K., Lai J.R. Designed protein mimics of the Ebola virus glycoprotein GP2 alpha-helical bundle: stability and pH effects. Protein Sci 2011, 20:1587-1596.
35. Jiang S., Zhao Q., Debnath A.K. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 2002, 8:563-580.
36. Olejnik J., Ryabchikova E., Corley R.B., Muhlberger E. Intracellular events and cell fate in filovirus infection. Viruses 2011, 3:1501-1531.
37. Wong G., Kobinger G.P., Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol 2014, 10:781-790.
38. Paessler S., Walker D.H. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol 2013, 8:411-440.
39. Hensley L.E., Jones S.M., Feldmann H., Jahrling P.B., Geisbert T.W. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr Mol Med 2005, 5:761-772.
40. Chan S.Y., Speck R.F., Ma M.C., Goldsmith M.A. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 2000, 74:4933-4937.
41. Ito H., Watanabe S., Takada A., Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 2001, 75:1576-1580.
42. Volchkova V.A., Dolnik O., Martinez M.J., Reynard O., Volchkov V.E. Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J Infect Dis 2011, 204(Suppl. 3):S941-S946.
43. Uebelhoer L.S., Albarino C.G., McMullan L.K., Chakrabarti A.K., Vincent J.P., Nichol S.T., et al. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antivir Res 2014, 106:86-94.
44. Bradfute S.B., Warfield K.L., Bray M. Mouse models for filovirus infections. Viruses 2012, 4:1477-1508.
45. Connolly B.M., Steele K.E., Davis K.J., Geisbert T.W., Kell W.M., Jaax N.K., et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999, 179(Suppl. 1):S203-S217.
46. Ebihara H., Zivcec M., Gardner D., Falzarano D., LaCasse R., Rosenke R., et al. A syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 2013, 207:306-318.
47. Twenhafel N.A., Mattix M.E., Johnson J.C., Robinson C.G., Pratt W.D., Cashman K.A., et al. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Vet Pathol 2013, 50:514-529.
48. Oestereich L., Ludtke A., Wurr S., Rieger T., Munoz-Fontela C., Gunther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir Res 2014, 105:17-21.
49. Hoenen T., Feldmann H. Reverse genetics systems as tools for the development of novel therapies against filoviruses. Expert Rev Anti Infect Ther 2014, 12:1253-1263.
50. Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
51. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1999, 179(Suppl. 1):S248-S258.
52. Mupapa K., Massamba M., Kibadi K., Kuvula K., Bwaka A., Kipasa M., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International scientific and technical committee. J Infect Dis 1999, 179(Suppl. 1):S18-S23.
53. Jahrling P.B., Geisbert J., Swearengen J.R., Jaax G.P., Lewis T., Huggins J.W., et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996, 11:135-140.
54. Dye J.M., Herbert A.S., Kuehne A.I., Barth J.F., Muhammad M.A., Zak S.E., et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012, 109:5034-5039.
55. Takada A., Feldmann H., Ksiazek T.G., Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003, 77:7539-7544.
56. Maruyama T., Rodriguez L.L., Jahrling P.B., Sanchez A., Khan A.S., Nichol S.T., et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999, 73:6024-6030.
57. Shedlock D.J., Bailey M.A., Popernack P.M., Cunningham J.M., Burton D.R., Sullivan N.J. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 2010, 401:228-235.
58. Parren P.W., Geisbert T.W., Maruyama T., Jahrling P.B., Burton D.R. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002, 76:6408-6412.
59. Oswald W.B., Geisbert T.W., Davis K.J., Geisbert J.B., Sullivan N.J., Jahrling P.B., et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007, 3:e9.
60. Marzi A., Yoshida R., Miyamoto H., Ishijima M., Suzuki Y., Higuchi M., et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012, 7:e36192.
61. Qiu X., Audet J., Wong G., Pillet S., Bello A., Cabral T., et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012, 4:138ra81.
62. Olinger G.G., Pettitt J., Kim D., Working C., Bohorov O., Bratcher B., et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 2012, 109:18030-18035.
63. Qiu X., Audet J., Wong G., Fernando L., Bello A., Pillet S., et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013, 3:3365.
64. Qiu X., Wong G., Fernando L., Audet J., Bello A., Strong J., et al. mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013, 5. 207ra143.
65. Giritch A., Marillonnet S., Engler C., van Eldik G., Botterman J., Klimyuk V., et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci U S A 2006, 103:14701-14706.
66. Jiang S., Lin K., Strick N., Neurath A.R. HIV-1 inhibition by a peptide. Nature 1993, 365:113.
67. Miller E.H., Harrison J.S., Radoshitzky S.R., Higgins C.D., Chi X., Dong L., et al. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem 2011, 286:15854-15861.
68. Higgins C.D., Koellhoffer J.F., Chandran K., Lai J.R. C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking. Bioorg Med Chem Lett 2013, 23:5356-5360.
69. Gump J.M., Dowdy S.F. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 2007, 13:443-448.
70. Basu A., Li B., Mills D.M., Panchal R.G., Cardinale S.C., Butler M.M., et al. Identification of a small-molecule entry inhibitor for filoviruses. J Virol 2011, 85:3106-3119.
71. Cote M., Misasi J., Ren T., Bruchez A., Lee K., Filone C.M., et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011, 477:344-348.
72. Shah P.P., Wang T., Kaletsky R.L., Myers M.C., Purvis J.E., Jing H., et al. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol Pharmacol 2010, 78:319-324.
73. Gehring G., Rohrmann K., Atenchong N., Mittler E., Becker S., Dahlmann F., et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014, 69:2123-2131.
74. Canonico P.G., Kende M., Luscri B.J., Huggins J.W. In-vivo activity of antivirals against exotic RNA viral infections. J Antimicrob Chemother 1984, 14(Suppl. A):27-41.
75. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989, 11(Suppl. 4):S750-S761.
76. Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res 2013, 100:446-454.
77. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mendenhall M., Bailey K.W., et al. Invitro and invivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007, 51:3168-3176.
78. Safronetz D., Falzarano D., Scott D.P., Furuta Y., Feldmann H., Gowen B.B. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother 2013, 57:4673-4680.
79. Rocha-Pereira J., Jochmans D., Dallmeier K., Leyssen P., Nascimento M.S., Neyts J. Favipiravir (T-705) inhibits invitro norovirus replication. Biochem Biophys Res Commun 2012, 424:777-780.
80. Morrey J.D., Taro B.S., Siddharthan V., Wang H., Smee D.F., Christensen A.J., et al. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antivir Res 2008, 80:377-379.
81. Smither S.J., Eastaugh L.S., Steward J.A., Nelson M., Lenk R.P., Lever M.S. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir Res 2014, 104:153-155.
82. Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005, 49:981-986.
83. Baranovich T., Wong S.S., Armstrong J., Marjuki H., Webby R.J., Webster R.G., et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses invitro. J Virol 2013, 87:3741-3751.
84. Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLoS One 2013, 8:e68347.
85. French nurse cured of Ebola contracted in Liberia. Agence France Presse. (accessed 22.11.14). http://www.msn.com/en-gb/news/world/french-nurse-cured-of-ebola-contracted-in-liberia/ar-BB7r1UJ.
86. Brincidofovir for Ebola. Chimerix, Inc. (accessed 22.11.14). http://www.chimerix.com/discovery-clinical-trials/brincidofovir/brincidofovir-for-ebola/.
87. Florescu D.F., Keck M.A. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti Infect Ther 2014, 12:1171-1178.
88. Price N.B., Prichard M.N. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol 2011, 1:548-554.
89. Warren T.K., Wells J., Panchal R.G., Stuthman K.S., Garza N.L., Van Tongeren S.A., et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014, 508:402-405.
90. Geisbert T.W., Hensley L.E., Kagan E., Yu E.Z., Geisbert J.B., Daddario-DiCaprio K., et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006, 193:1650-1657.
91. Geisbert T.W., Lee A.C., Robbins M., Geisbert J.B., Honko A.N., Sood V., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010, 375:1896-1905.
92. Warren T.K., Shurtleff A.C., Bavari S. Advanced morpholino oligomers: a novel approach to antiviral therapy. Antivir Res 2012, 94:80-88.
93. Warren T.K., Warfield K.L., Wells J., Swenson D.L., Donner K.S., Van Tongeren S.A., et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010, 16:991-994.
94. Choi J.H., Croyle M.A. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs 2013, 27:565-583.
95. Cardenas W.B. Evasion of the interferon-mediated antiviral response by filoviruses. Viruses 2010, 2:262-282.
96. Kuhl A., Pohlmann S. How Ebola virus counters the interferon system. Zoonoses Public Health 2012, 59(Suppl. 2):116-131.
97. Jahrling P.B., Geisbert T.W., Geisbert J.B., Swearengen J.R., Bray M., Jaax N.K., et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999, 179(Suppl. 1):S224-S234.
98. Smith L.M., Hensley L.E., Geisbert T.W., Johnson J., Stossel A., Honko A., et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 2013, 208:310-318.
99. Ansari A.A. Clinical features and pathobiology of ebolavirus infection. J Autoimmun 2014.
100. Geisbert T.W., Hensley L.E., Jahrling P.B., Larsen T., Geisbert J.B., Paragas J., et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003, 362:1953-1958.
101. Hensley L.E., Stevens E.L., Yan S.B., Geisbert J.B., Macias W.L., Larsen T., et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007, 196(Suppl. 2):S390-S399.
102. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Stroher U., Grolla A., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007, 3:e2.
103. Gunther S., Feldmann H., Geisbert T.W., Hensley L.E., Rollin P.E., Nichol S.T., et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011, 204(Suppl. 3):S785-S790.
104. Groseth A., Feldmann H., Strong J.E. The ecology of Ebola virus. Trends Microbiol 2007, 15:408-416.
105. Pourrut X., Kumulungui B., Wittmann T., Moussavou G., Delicat A., Yaba P., et al. The natural history of Ebola virus in Africa. Microbes Infect 2005, 7:1005-1014.
106. Reed D.S., Lackemeyer M.G., Garza N.L., Sullivan L.J., Nichols D.K. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect 2011, 13:930-936.
107. Lu L., Liu Q., Jiang S. Biosecurity and biosafety in research on emerging pathogens. Emerg Microbes Infect 2012, 1:e44.